Cargando…
Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
Treprostinil diolamine is the first oral prostacyclin approved for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. Clinical studies have demonstrated modest benefit as monotherapy, whereas no difference in exercise capacity was observed with combination therapy....
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941659/ https://www.ncbi.nlm.nih.gov/pubmed/29609511 http://dx.doi.org/10.1177/1753466618766490 |